163 related articles for article (PubMed ID: 19496668)
1. Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors.
Bailey DB; Rassnick KM; Dykes NL; Pendyala L
Am J Vet Res; 2009 Jun; 70(6):770-6. PubMed ID: 19496668
[TBL] [Abstract][Full Text] [Related]
2. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors.
Bailey DB; Rassnick KM; Erb HN; Dykes NL; Hoopes PJ; Page RL
Am J Vet Res; 2004 Nov; 65(11):1502-7. PubMed ID: 15566088
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serum iohexol clearance for use in predicting carboplatin clearance in cats.
Bailey DB; Rassnick KM; Prey JD; Dykes NL
Am J Vet Res; 2009 Sep; 70(9):1135-40. PubMed ID: 19719430
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
5. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study.
Kisseberth WC; Vail DM; Yaissle J; Jeglum KA; Couto CG; Ward H; Khanna C; Obradovich JE
J Vet Intern Med; 2008; 22(1):83-8. PubMed ID: 18289293
[TBL] [Abstract][Full Text] [Related]
7. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
Newell DR; Pearson AD; Balmanno K; Price L; Wyllie RA; Keir M; Calvert AH; Lewis IJ; Pinkerton CR; Stevens MC
J Clin Oncol; 1993 Dec; 11(12):2314-23. PubMed ID: 8246021
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
Ghazal-Aswad S; Tilby MJ; Lind M; Baily N; Sinha DP; Calvert AH; Newell DR
Ann Oncol; 1999 Mar; 10(3):329-34. PubMed ID: 10355578
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
Millward MJ; Webster LK; Toner GC; Bishop JF; Rischin D; Stokes KH; Johnston VK; Hicks R
Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211
[TBL] [Abstract][Full Text] [Related]
13. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
Morrow A; Garland C; Yang F; De Luna M; Herrington JD
J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
[TBL] [Abstract][Full Text] [Related]
14. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
15. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
Holweger K; Lipp HP; Beijnen JH; Bokemeyer C; Hartmann JT
Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060
[TBL] [Abstract][Full Text] [Related]
17. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
Shepherd ST; Gillen G; Morrison P; Forte C; Macpherson IR; White JD; Mark PB
Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148
[TBL] [Abstract][Full Text] [Related]
18. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
Thomas H; Boddy AV; English MW; Hobson R; Imeson J; Lewis I; Morland B; Pearson AD; Pinkerton R; Price L; Stevens M; Newell DR
J Clin Oncol; 2000 Nov; 18(21):3614-21. PubMed ID: 11054434
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert AH; Newell DR; Gumbrell LA; O'Reilly S; Burnell M; Boxall FE; Siddik ZH; Judson IR; Gore ME; Wiltshaw E
J Clin Oncol; 1989 Nov; 7(11):1748-56. PubMed ID: 2681557
[TBL] [Abstract][Full Text] [Related]
20. Hematologic and systemic toxicoses associated with carboplatin administration in cats.
Hahn KA; McEntee MF; Daniel GB; Legendre AM; Nolan ML
Am J Vet Res; 1997 Jun; 58(6):677-9. PubMed ID: 9185979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
